Cimalgex Tablet 8mg - Per Tablet

Cimalgex may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase Cimalgex if you have or are in the process of arranging such a prescription. See information bar for further details.  

Cimalgex 8mg chewable tablets for dogs are oblong, white to pale brown, chewable tablets with a break-line on both sides. Cimaglex tablets can be divided into equal halves.

Cimalgex is used for the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs.

Cimalgex tablets can be administered with or without food. The tablets are flavoured and studies show they are likely to be taken voluntarily by most dogs. The recommended dose of cimicoxib is 2 mg per kg bodyweight, once daily. Treatment duration:

Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of the attending veterinarian. Relief of pain and inflammation associated with osteoarthritis: 6 months. For longer-term treatment, regular monitoring should be undertaken by the veterinarian.

Contra-indications, warnings, etc.

Do not use Cimalgex in dogs less than 10 weeks of age. Do not use in dogs suffering from gastrointestinal disorders or haemorrhagic disorders Do not use Cimalgex concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not use in case of hypersensitivity to cimicoxib or to any of the excipients. Do not use in breeding, pregnant and lactating animals.

Special precauctions for use in animals: Since the safety of the medicinal product has not been adequately demonstrated in young animals, careful monitoring is advised during the treatment of young dogs aged less than 6 months. Use of Cimalgex in dogs suffering from impaired cardiac, renal or hepatic function, may involve additional risk. If such use cannot be avoided, these animals require careful veterinary monitoring. Avoid using Cimalgex in any animals which are dehydrated, hypovolaemic or hypotensive, as it may increase the risk of renal toxicity. Use this veterinary medicinal product under strict veterinary monitoring where there is a risk of gastrointestinal ulceration, or if the animal previously displayed intolerance to NSAIDs. Special precautions to be taken by the person administering the veterinary medicinal product to animals: Cimicoxib may cause skin sensitisation. Wash hands after use. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. People with a known hypersensitivity to cimicoxib should avoid contact with Cimalgex. Administer the veterinary medicinal product with caution. Use during pregnancy, lactation or lay. Do not use in breeding, pregnant or lactating bitches. Although no data are available in dogs, studies with laboratory animals have shown effects on their fertility and foetal development.

Interaction with other medicinal products and other forms of interaction. Cimalgex should not be administered in conjunction with corticosteroids or other NSAIDs. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed before the commencement of treatment with Cimalgex. The treatment-free period should take into account the pharmacokinetic properties of the veterinary medicinal product used previously. In an overdose study where 3 times (5.8 to 11.8 mg/kg body weight) and 5 times (9.7 to 19.5 mg/kg body weight) the recommended dose was administered to dogs for a period of 6 months, a dose related increase in gastrointestinal disturbances, which affected all dogs in the highest dose group, was noted. As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised dogs. Pharmaceutical precautions. Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Any remaining half tablets should be discarded after 2 days storage in the blisters. Any remaining half tablets should be discarded after 90 days storage in the bottle.